Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
TPG Capital acquisition of Convey Health Solutions and related financing
Davis Polk advised TPG Capital, the private equity platform of global alternative asset firm TPG, on its acquisition of…
Elanco Acquires Bayer’s Animal Health Business
Davis Polk is advising Duff & Phelps as financial adviser to the Board of Directors of Elanco Animal Health Incorporated…
Deciphera Pharmaceuticals Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Deciphera…
Portola Pharmaceuticals, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers and the lead manager in connection with a $258.8 million public offering…
Stemline Therapeutics, Inc. Common Stock Offering
Davis Polk advised the underwriters in connection with the SEC-registered offering of 5,750,000 shares of common stock of…
Allakos Inc. $402 Million Follow-On Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the follow-on…
$1.075 billion financing for Option Care's combination with BioScrip
Davis Polk advised the administrative agent, joint lead arranger and joint bookrunner in connection with a $925 million…
PTC Therapeutics, Inc. $125 Million SEC-Registered At-The-Market Offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by PTC Therapeutics, Inc. of…
Oryzon Genomics’s Private Placement of Ordinary Shares
Davis Polk advised Oryzon Genomics, S.A. on its €20 million private placement of its ordinary shares pursuant to a capital…
Tax counsel to Pfizer on the combination of its Upjohn business with Mylan
Davis Polk is acting as special tax counsel to Pfizer Inc. on the combination of its off-patent branded and generic…